Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Wound Care ; 24(12): 582-6, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26654738

RESUMEN

OBJECTIVE: Polyhexamethylene biguanide (PHMB) is a novel wound antiseptic solution that has a broad antimicrobial spectrum and wound healing promoting effect, with minimal side effects. The aim of present study was to demonstrate the efficacy of the PHMB on the bacterial burden of non-healing wounds, the reduction in wound size or closure of the wound in comparison to Ringer's lactate solution (RLS) after 21 days of wound dressing. A second objective was to investigate the differences in the C-reactive protein (CRP) levels and white blood cell (WBC) counts between the two groups. METHOD: In this prospective and open-cohort clinical study, patients who underwent cardiac surgery between July 2006 and August 2008 were included and placed in one of two groups, PHMB or RLS, by the block randomisation method. A wound care team, consisting of two surgeons, a wound care nurse and a microbiologist, was created. Classic moist dressings and wet compresses during dressing changes were applied at least once a day or as needed. During the 21 days of hospitalisation the team collected data on the wound healing status daily, on infection parameters every third day, and wound tissue for culture weekly. RESULTS: There were 40 patients recruited of which 9 were excluded, leaving 31 in the intention-to-treat analysis. Of these 15 received PHMB and 16 received RLS. Overall 17 of 31 (66.7% PHMB group, 43.8% RLS group, p=0.181) patients were treated successfully by closure of surgically sutured wounds or healing by secondary intention, the wound tissue cultures of 19 of 31 patients (47.4% PHMB, 52.6% RLS, p=0.886) were negative, and wound size of all the patients were significantly reduced in clinical observations. Although the CRP levels were reduced significantly within group comparisons in both groups (p<0.001), it was significantly lower after 12 days (p<0.05) in the PHMB group compared with the RLS group. CONCLUSION: The results of this study emphasise that the successful treatment of chronic non-healing wounds require a multidisciplinary team approach under the control of a wound care specialist. Whatever the disinfectant used, consistency in the approach to treatment may be more important. We suggest that increasing the use of PHMB and adoption of this team approach in other cardiac centres or other populations may decrease the healing period, especially in chronic non-healing wounds.


Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Biguanidas/uso terapéutico , Infección de la Herida Quirúrgica/tratamiento farmacológico , Infección de la Herida Quirúrgica/microbiología , Anciano , Infecciones Bacterianas/sangre , Proteína C-Reactiva/análisis , Estudios de Cohortes , Femenino , Humanos , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Infección de la Herida Quirúrgica/sangre , Procedimientos Quirúrgicos Torácicos , Cicatrización de Heridas/efectos de los fármacos
2.
Niger J Clin Pract ; 18(1): 120-3, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25511356

RESUMEN

PURPOSE: Vessels with high venous flow rate are needed for the application of hemodialysis in patients needing chronic hemodialysis. The increase in the number of chronic hemodialysis patients has led to an increase in the number of vascular surgical operations. The aim of this study was to evaluate the results of polytetraflouroethylen (PTFE) graft arteriovenous fistula (AVF) applications. MATERIALS AND METHODS: Files of 596 patients who received hemodialysis treatment at the Nephrology Unit of the Sanliurfa Mehmet Akif Inan State Hospital between September 2009 and 2013 were retrospectively analyzed. PTFE grafts and autogenous AVFs applied in 22 patients were analyzed, and demographic data and PTFE graft associated complications of these patients were evaluated. RESULTS: We found that the graft patency duration (months ± standard deviation) and the patency after graft revision were 16 ± 13 and 83.3%. Complications were detected in 14 patients (63%). One patient developed hematoma in early stages. CONCLUSIONS: We conclude that even if PFTE graft AVF applications cause significant complications, the procedure has a high patency rate after graft revision.


Asunto(s)
Derivación Arteriovenosa Quirúrgica , Implantación de Prótesis Vascular , Prótesis Vascular , Fallo Renal Crónico/terapia , Politetrafluoroetileno , Complicaciones Posoperatorias/cirugía , Diálisis Renal/métodos , Adulto , Anciano , Aneurisma/cirugía , Femenino , Oclusión de Injerto Vascular/cirugía , Hematoma/cirugía , Humanos , Masculino , Persona de Mediana Edad , Hemorragia Posoperatoria , Reoperación , Estudios Retrospectivos , Trombosis/cirugía , Factores de Tiempo , Grado de Desobstrucción Vascular
3.
Cardiovasc J Afr ; 26(1): e11-3, 2015 Feb 23.
Artículo en Inglés | MEDLINE | ID: mdl-25784496

RESUMEN

Although some of the aetiological factors of seizure, such as cerebral microemboli, cerebral oedema, hypoperfusion, cerebral hypoxia and metabolic encephalopathy cannot be completely controlled during cardiac surgery, cautious management of all steps in the procedure may prevent the administrative causes of seizure. Cefazolin, which is known to be a proconvulsant agent, may be a suspected agent of seizure complications in patients with renal insufficiency. Surprisingly, intravenous bolus administration of cefazolin may also trigger seizure in patients with normal renal function. In this case report, a complication of generalised seizure after cardiac surgery with intravenous bolus administration of cefazolin is described, along with a brief review of the literature.


Asunto(s)
Antibacterianos/efectos adversos , Cefazolina/efectos adversos , Puente de Arteria Coronaria/efectos adversos , Convulsiones/inducido químicamente , Administración Intravenosa , Antibacterianos/administración & dosificación , Anticonvulsivantes/uso terapéutico , Cefazolina/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Convulsiones/diagnóstico , Convulsiones/tratamiento farmacológico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda